ADAMS THOMAS PHD 4

4 · Cardiff Oncology, Inc. · Filed Jun 14, 2021

Form 4

Period: 2021-06-10

Director

Transactions

Other
Stock Options
2021-06-10+173,145→ 477,870 total
Exercise: $2.60From: 2020-12-29Exp: 2023-06-10→ Common Stock (173,145 underlying)
Other
Stock Options
2021-06-10+223→ 477,870 total
Exercise: $5.18From: 2017-01-04Exp: 2023-06-10→ Common Stock (223 underlying)
Other
Stock Options
2021-06-10+272→ 477,870 total
Exercise: $447.84Exp: 2023-06-10→ Common Stock (272 underlying)
Other
Stock Options
2021-06-10+223→ 477,870 total
Exercise: $7.18From: 2016-03-17Exp: 2023-06-10→ Common Stock (223 underlying)
Other
Stock Options
2021-06-10+530→ 477,870 total
Exercise: $51.84From: 2018-10-04Exp: 2023-06-10→ Common Stock (530 underlying)
Other
Stock Options
2021-06-10+755→ 477,870 total
Exercise: $21.60From: 2019-01-23Exp: 2023-06-10→ Common Stock (755 underlying)
Other
Stock Options
2021-06-10+298,320→ 477,870 total
Exercise: $2.48From: 2020-12-29Exp: 2023-06-10→ Common Stock (298,320 underlying)

Footnotes (3)

[F1]Expiration date of the stock options was extended to June 10, 2023.
[F2]7,338 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.
[F3]In connection with the Reporting Person's separation agreement dated December 21, 2020, the Compensation Committee accelerated the vesting of such stock options to December 29, 2020.

Documents

1 file